LogicBio Therapeutics Inc. priced its IPO of 7 million common shares at $10 apiece to raise gross proceeds of about $70 million.
The genome editing company, which focuses on developing medicines to durably treat rare diseases in patients with significant unmet medical need, also plans to grant the underwriters an option to buy up to an additional 1,050,000 shares.
LogicBio's common stock is expected to start trading on the Nasdaq Global Market on Oct. 19 under the ticker symbol LOGC.
The offering is expected to close Oct. 23.
Jefferies, Barclays and William Blair are acting as joint book-running managers, while Chardan is acting as the lead manager for the IPO.